Mostrar el registro sencillo del ítem

dc.contributor.author
Travella, Ana Carolina  
dc.contributor.author
Ripollés, Lorena  
dc.contributor.author
Aventin, Anna  
dc.contributor.author
Rodríguez, Andrea  
dc.contributor.author
Bezares, Raimundo F.  
dc.contributor.author
Caballín, María Rosa  
dc.contributor.author
Slavutsky, Irma Rosa  
dc.date.available
2017-07-18T20:01:05Z  
dc.date.issued
2013-06  
dc.identifier.citation
Travella, Ana Carolina; Ripollés, Lorena; Aventin, Anna; Rodríguez, Andrea; Bezares, Raimundo F.; et al.; Structural alterations in chronic lymphocytic leukemia: cytogenetic and FISH analysis; Wiley; Hematological Oncology; 31; 2; 6-2013; 339-347  
dc.identifier.issn
0278-0232  
dc.identifier.uri
http://hdl.handle.net/11336/20864  
dc.description.abstract
In this study, we described cytogenetics and fluorescence in situ hybridization (FISH) analysis performed in chronic lymphocytic leukaemia (CLL) patients with structural alterations. Results were correlated with clinical characteristics. A total of 38 CLL patients: 16 cases with complex and 22 with simple karyotypes were studied. For comparison of clinical parameters, a control group of 78 CLL patients with normal karyotype and without FISH genomic alterations were also evaluated. We found 38 structural abnormalities not previously described in the literature, 28 (74%) of them were translocations. In cases with complex karyotypes, chromosomes 6, 8 and 13 were the most frequently involved in new alterations (nine each), followed by chromosomes 12, 14 and 15 (six each). Chromosome 8p was particularly involved in losses, being 8p21-pter the commonest region of overlap. Cases with simple karyotypes, showed del(6q) as the most frequent alteration (39%). Del(9)(q11) was recurrent in our series. Analysis of clinical parameters showed significant differences in white blood count (p = 0.005) and platelet count (p = 0.015) between patients with structural alterations and the control group. In addition, patients with structural alterations had a significantly shorter time to first treatment (TFT) (29 months) than the control group (69 months) (p = 0.037). Cases with complex karyotypes had a lower proportion of patients in Rai 0 clinical stage (15.4% vs 75%) (p = 0.005) and higher β2 microglobulin levels (3.3 vs 2.5 µg/mL) (p = 0.037) than those with simple karyotypes. Furthermore, a shorter TFT (13 months) and overall survival (56 months) in the complex karyotypes group compared with controls (69 and 144 months, respectively) (p = 0.015 and p = 0.005, respectively) were also found. Our results support the importance of cytogenetic analysis for clinical outcome in CLL and suggest that the diversity of genomic alterations is much greater than previously appreciated.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Wiley  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Chronic Lymphocytic Leukaemia  
dc.subject
Cytogenetics  
dc.subject
Fish  
dc.subject
Complex Karyotypes  
dc.subject.classification
Genética Humana  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Structural alterations in chronic lymphocytic leukemia: cytogenetic and FISH analysis  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2017-07-17T21:14:00Z  
dc.journal.volume
31  
dc.journal.number
2  
dc.journal.pagination
339-347  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Hoboken  
dc.description.fil
Fil: Travella, Ana Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina  
dc.description.fil
Fil: Ripollés, Lorena. Universitat Autònoma de Barcelona; España  
dc.description.fil
Fil: Aventin, Anna. Hospital de Sant Pau; España  
dc.description.fil
Fil: Rodríguez, Andrea. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex"; Argentina  
dc.description.fil
Fil: Bezares, Raimundo F.. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Dr. Teodoro Álvarez"; Argentina  
dc.description.fil
Fil: Caballín, María Rosa. Universitat Autònoma de Barcelona; España  
dc.description.fil
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina  
dc.journal.title
Hematological Oncology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://onlinelibrary.wiley.com/doi/10.1002/hon.2025/abstract  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/hon.2025